Revelation Biosciences touts positive PRIME CKD results

Revelation Biosciences, Inc. reported a clinical milestone by announcing positive top-line results from its PRIME phase 1b clinical study in patients with chronic kidney disease.

Rhea-AI Filing Summary

Revelation Biosciences, Inc. reported a clinical milestone by announcing positive top-line results from its PRIME phase 1b clinical study in patients with chronic kidney disease. The company described the results as “groundbreaking” in a press release issued on September 9, 2025.

Alongside the press release, Revelation Biosciences made a corporate presentation with the top-line data available to the public on its website. Both the press release and the presentation are attached as exhibits to this report, but the company states that this information will be furnished rather than filed under the Exchange Act, which means it is not subject to certain liability provisions unless specifically incorporated into other filings.

Positive

• Positive phase 1b clinical results in chronic kidney disease described as “groundbreaking” may support continued development of the company’s program.

Negative

• None.

Insights

Biotech and clinical-stage investments analyst

Revelation reports positive phase 1b kidney disease data, an early but important clinical step.

Revelation Biosciences highlights “groundbreaking” positive top-line results from its PRIME phase 1b clinical study in chronic kidney disease patients. Phase 1b studies typically focus on safety and early signals of activity in a target population, so favorable outcomes can support continued development and potential advancement into later-stage trials.

The company also released a corporate presentation with top-line data, suggesting an intent to give stakeholders more detail on the results and development plans. Actual long-term impact will depend on full data, subsequent trial design, and regulatory interactions, which are not detailed here and would likely be discussed in future disclosures.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Revelation Biosciences (REVBW) announce in this 8-K?

Revelation Biosciences announced positive top-line results from its PRIME phase 1b clinical study in chronic kidney disease patients and issued a press release describing the results as “groundbreaking.”

What is the PRIME phase 1b clinical study mentioned by REVBW?

The PRIME study is a phase 1b clinical trial in chronic kidney disease patients. Revelation Biosciences reported positive top-line results from this study, indicating an encouraging early clinical outcome.

How did Revelation Biosciences share the PRIME study results with investors?

The company issued a press release titled “Revelation Biosciences Announces Groundbreaking Top-line Results from PRIME Clinical Study” and made a corporate presentation with the top-line data available to the public on its website.

Are the PRIME study materials considered filed or furnished by Revelation Biosciences?

The company states that the information in Item 8.01 and Exhibits 99.1 and 99.2 will be furnished, not filed, under the Exchange Act and will not be subject to Section 18 liabilities unless expressly incorporated into another filing.

What exhibits did Revelation Biosciences attach related to the PRIME study?

Revelation Biosciences attached Exhibit 99.1 (the September 9, 2025 press release), Exhibit 99.2 (a corporate presentation dated September 9, 2025), and Exhibit 104 (the cover page interactive data file).

Does this 8-K disclose any financial results for Revelation Biosciences (REVBW)?

This report focuses on clinical results and related disclosures for the PRIME phase 1b study in chronic kidney disease and does not present financial results.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 09/09/2025 - 08:02 AM Learn about SEC filing dates

false00018105600001810560us-gaap:CommonStockMember2025-09-092025-09-0900018105602025-09-092025-09-090001810560revb:RedeemableWarrantsEachExercisableForA150400ThShareOfCommonStockAtAnExercisePriceOf579600PerShareMember2025-09-092025-09-09

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 09, 2025

REVELATION BIOSCIENCES, INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-39603	84-3898466
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
4660 La Jolla Village Drive Suite 100
San Diego, California				92122
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (650) 800-3717

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, par value $0.001 per share		REVB		The Nasdaq Stock Market LLC
Redeemable warrants, each exercisable for a 1/50,400th share of common stock at an exercise price of $579,600 per share		REVBW		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On September 9, 2025, Revelation Biosciences, Inc. (the “Company”) issued a press release titled “Revelation Biosciences Announces Groundbreaking Top-line Results from PRIME Clinical Study” announcing positive clinical results from the PRIME phase 1b clinical study in chronic kidney disease patients. Additionally, the Company made a corporate presentation with the top-line data available to the public, the corporate presentation can be found on the Company’s website. A copy of the press release and presentation are attached to this Current Report on Form 8-K as Exhibit 99.1 and Exhibit 99.2, respectively and are incorporated herein by reference.

The information in Item 8.01, in Exhibit 99.1 and Exhibit 99.2 will not be treated as “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. This information will not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or into another filing under the Exchange Act, unless that filing expressly incorporates this information by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Press release, dated September 9, 2025
99.2		Corporate Presentation dated September 9, 2025
104		Cover Page Interactive Data File (embedded with the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

		REVELATION BIOSCIENCES, INC.
Date: September 9, 2025	By:	/s/ Chester S. Zygmont, III
		Chester S. Zygmont, III Chief Financial Officer (principal financial and accounting officer)